ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPUL
Key facts
| Status | Awarded |
|---|---|
| Estimated value | $108,841,769 |
| Submission deadline | Deadline not published |
| Published | Jun 9, 2022 |
| Buyer | Office of Assistant Secretary for Preparedness and Response |
| Country | United States |
| CPV code | NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN13 |
| Source | USAspending.gov Federal Contract Awards ↗ |
- Status
- Awarded
- Estimated value
- $108,841,769
- Submission deadline
- Deadline not published
- Published
- Jun 9, 2022
- Country
- United States
- CPV code
- NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN13
- Source
- USAspending.gov Federal Contract Awards
Contract outcome & evergreen alternatives
This notice is no longer open for submissions. The original remains available for reference.
| Awarded supplier / winner | Registration / LEI number | Country | Awarded contract amount | Award date |
|---|---|---|---|---|
| CROSSJECT SA | US-UEI: NLXZHCL3NLL3 | United States | $108,841,769 | Jun 9, 2022 |
Checked:
The original notice takes precedence. Its status and conditions can change after collection.
Description
ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+
Awarding Agency: Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response.
NAICS 541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
PSC AN13: HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT.
Period of Performance: 2022-06-22 to 2030-06-21.